Beleodaq®

Onxeo confirms receipt of the $25M milestone payment on Beleodaq® – Onxeo bekræfter modtagelsen af milepælsbetaling på USD 25 mio. for Beleodaq®

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq® by the FDA. Early July 2014, Beleodaq® was granted by the U.S. Food and Drug Administration (FDA)…read more →

Onxeo strengthens Beleodaq® patent protection in the U.S. until 2027 – Onxeo styrker patentbeskyttelsen af Beleodaq® i USA indtil 2027

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, today announced that the U.S. Patent Office will grant a new patent for Beleodaq® (Belinostat U.S. commercial name) on September 16th 2014. In addition to the existing patent, covering the chemical structure of Beleodaq®, this new patent also…read more →

FDA approval of Beleodaq™ (belinostat)

• Accelerated Approval of Topotarget’s Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma • Early Action follows Priority Review 5 weeks before PDUFA Date • Trigger milestone payment of USD 25 million to Topotarget • Beleodaq™ is expected to be available to patients in July 2014 and will be launched through Spectrum Pharmaceutical’s existing oncology…read more →

12